Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-01-04 DOI:10.1080/2162402x.2023.2300520

Manuela Lizarralde-Guerrero, Laura Zucaro, Guido Kroemer, Jonathan G. Pol

引用次数: 0

Abstract

Advances in single-cell RNA and T cell receptor (TCR) sequencing allow to study the specificity and functionality of tumor-infiltrating T lymphocytes. A recent study unravels fundamental difference...

查看原文本刊更多论文

对浸润结直肠癌的 T 淋巴细胞进行单细胞分析：特异性难题

单细胞 RNA 和 T 细胞受体 (TCR) 测序技术的进步有助于研究肿瘤浸润 T 淋巴细胞的特异性和功能性。最近的一项研究揭示了...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.